Navigation Links
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Date:8/12/2008

the Dresden Technical University. In 1995, he received the Galenus-von-Pergamon prize for having developed alkylphospholipids as a new class of anti-tumor agents. Prof. Engel is the author of more than 250 scientific articles, several books and he applied for more than 100 patent applications.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
2. AEterna Zentaris Sells Quebec City Building for $7.1 million
3. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
4. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
5. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
6. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
7. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
8. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Announces Changes to its Management Team
11. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... September 2, 2015 Biovista ... Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. Hierbei ... Genomics Institute. Biovista unterstützt mit seiner ... die Behandlung anderer Krankheiten als denen, für die ... und sein Team bei der Wylder Nation ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's new $100,000 waste ... energy process and continue to contribute to the sustainability of our natural resources. ... Energy process has been operating at their Mexico facility, Recicladora Temarry, for the ...
(Date:9/1/2015)... STOCKHOLM , September 2, 2015 /PRNewswire/ ... sich primär auf die Forschung und Entwicklung ... beispielsweise Allergien, chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, ... die Zusage, dass sein neues Medikament patentiert ... Superantigen, das Allergien bei Kindern verhindert und ...
(Date:9/1/2015)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical ... antiviral therapies, announced today that it will present at ... Investment Conference sponsored by H.C. Wainwright & ... Regis Hotel in New York, NY ... Executive Officer, will provide an overview of the Company,s ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Temarry Recycling’s New $100,000 Waste to Energy Renovation 2Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... , June 29, 2010 Cardio3,BioSciences, a leading Belgian ... today,announces positive safety data and preliminary efficacy results from its,clinical trial ... , , ... Results showed C-Cure to have a very good safety profile with ...
... , June 29 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrine therapy, ... 5-FU Refractory Patients from a Randomized Phase 2 Study ... (CAP) in Patients with 2nd or 3rd Line Metastatic ...
... , DALLAS , June 29, 2010 , ... - ReportsandReports Announces it Will Carry the Disease ... , , ... , ...
Cached Biology Technology:Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 3Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 4Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 5Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer 2Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer 3Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer 4Disease and Therapy Review: Asthma Now Available at ReportsandReports 2Disease and Therapy Review: Asthma Now Available at ReportsandReports 3Disease and Therapy Review: Asthma Now Available at ReportsandReports 4Disease and Therapy Review: Asthma Now Available at ReportsandReports 5
(Date:8/24/2015)... , Aug. 24, 2015  Based on its recent ... DERMALOG with the 2015 African Biometrics Company of the Year ... achieved substantial commercial success in Africa . ... , where it has implemented one of the largest biometric ... as well as the Central Bank of Nigeria ...
(Date:8/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... Smart Card Alliance and the EMV Migration Forum.  ... Smart Card Alliance Latin America (SCALA) Chapter provides NXT-ID, ... thought leaders promoting adoption of smart card technology. ...
(Date:8/18/2015)... , Aug. 17, 2015 Research and ... of the "Global Biometric Authentication & Identification ... Estimation & Forecast, 2015-2020" report to their ... and identification systems market is expected to grow ... to 2020 and generate over $25 billion (approximately) ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... The University of Michigan,s first human embryonic stem cell ... Health,s registry, making the cells available for federally-funded research. It ... the University of Michigan to be placed on the registry. ... line, derived in October 2010 from a cluster of about ...
... as coffee and soda are the pick-me-ups of choice for ... sleep problems. Caffeine Zone software app developed by Penn State ... a mental boost and when it could hurt their sleep ... it with information on the effects of caffeine to produce ...
... among species of a North American group of prickly pear ... of hybrid origin. Those widespread species likely originated from hybridization ... America. This study was published in the open access journal ... cacti (of the genus Opuntia ) are ...
Cached Biology News:U-M human embryonic stem cell line placed on national registry 2U-M human embryonic stem cell line placed on national registry 3Best time for a coffee break? There's an app for that 2Chromosome analyses of prickly pear cacti reveal southern glacial refugia 2
Vybrant® Multidrug Resistance Assay Kit...
... pipets ,Angled acrylic pipet rack offers easy access ... pipet cans. Constructed of 6 mm (1/4 in.) thick ... 76 mm H x 289 mm D (3 x ... W x 406 mm H x 292 mm D ...
...
... cell culture systems provide an integrated ... staining and imaging. Each system uses ... optical-quality coverslips in cell culture plates. ... and ready to use. Individual chambered ...
Biology Products: